Lubris Announces Outlicensing Of Its Proprietary Recombinant Human Lubricin For Use In Ophthalmology To Major Pharma Company

Thursday, April 6, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, April 6, 2017 /PRNewswire/ --áLÁbris BioPharma announced today that Novartis has exercised an option to in-license

ECF843, LÁbris' proprietary recombinant human lubricin for ophthalmic indications worldwide (outside Europe) including the treatment of dry eye. The closing of the deal is subject to customary closing conditions including
regulatory approvals. LÁbris retains rights to commercialize products outside of ophthalmology. Financial terms were not disclosed.

"We are very excited to partner with Novartis, the world's leading pharmaceutical company to bring our recombinant human lubricin to patients in need of new treatment options for ophthalmic diseases like dry eye," said Edward R. Truitt, III, LÁbris' CEO.á In a recent clinical trial, ECF843 demonstrated statistically significant improvements in multiple signs and symptoms of dry eye disease with no adverse events and rapid onset of action.

Lubricin is an endogenous human protein which functions as an anti-adhesive, anti-inflammatory, biologic lubricant.á Its general role in the body is to protect tissue surfaces from damage and degradation resulting from normal friction and wear.á However, as a result of age, autoimmune disease and/or injury the normal production of lubricin can become compromised resulting in damage to tissues like the cornea and cartilage leading to diseases like dry eye and osteoarthritis.

"Lubricin has the potential to help millions of patients across multiple indications," said Harry Barnett, LÁbris' Executive Chairman. "The Novartis in-license represents a significant achievement for LÁbris as we continue to execute on our strategy for bringing this protein to market in multiple therapeutic areas including dry eye, xerostomia, osteoarthritis, and other age and inflammation-related conditions."á

About LÁbris BioPharmaLÁbris BioPharma is a privately held development-stage life science company producing and commercializing a recombinant version of the human protein, Lubricin. Lubricin is expressed in numerous parts of the human body and plays an important role in protecting surfaces from damage and wear. Key opinion leaders and clinicians worldwide are focusing their research efforts on using lubricin to improve the lives of millions of people with a host of unmet medical needs including dry eye, osteoarthritis, rheumatoid arthritis, post-surgical adhesions, xerostomia and interstitial cystitis.á You can learn more at áwww.lubris.net.

Media ContactAndrea Mowery-Donahue [email protected]

Lubris BioPharma Ě111 Speen Street ĚFramingham, MA Ě [email protected] Ě lubris.net

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lubris-announces-outlicensing-of-its-proprietary-recombinant-human-lubricin-for-use-in-ophthalmology-to-major-pharma-company-300435525.html

SOURCE Lubris BioPharma



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook